Skip to Content
Merck

Key Documents

View All Documentation

V7264

Venlafaxine hydrochloride

≥98% (HPLC), serotonin-noradrenaline reuptake inhibitor, powder

Synonym(s):

(+/-)-1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride, Effexor

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C17H27NO2 · HCl
CAS Number:
99300-78-4
Molecular Weight:
313.86
UNSPSC Code:
12352200
PubChem Substance ID:
329829062
NACRES:
NA.77
MDL number:
MFCD03658865
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated, protect from light
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Venlafaxine hydrochloride, ≥98% (HPLC), powder

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated, protect from light

color

white

solubility

H2O: >10 mg/mL

originator

Wyeth

SMILES string

Cl[H].COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2

InChI

1S/C17H27NO2.ClH/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14;/h7-10,16,19H,4-6,11-13H2,1-3H3;1H

InChI key

QYRYFNHXARDNFZ-UHFFFAOYSA-N

Gene Information

human ... SLC6A2(6530), SLC6A4(6532)

Biochem/physiol Actions

Venlafaxine is a dual serotonin-noradrenaline reuptake inhibitor that displays Ki values of 82 and 2480 nM respectively. It is a general class antidepressant.
Venlafaxine is an antidepressant. The mechanism of the antidepresant action of venlafaxine in humans is associated with its potentiation of neurotransmitter activity in the CNS. Venlafaxine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and weak inhibitor of dopamine reuptake. Venlafaxine has no significant activity for muscarinic, histaminergic, or α-1 adrenergic receptors in vitro. Venlafaxine does not possess MAO inhibitor activity.

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Wyeth. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Venlafaxine hydrochloride

pictograms

Environment
GHS09

hcodes

H411

Hazard Classifications

Aquatic Chronic 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000403332
0000364159
0000364157
0000303085
0000364159

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anna Freixa et al.
Frontiers in microbiology, 9, 1426-1426 (2018-07-19)
Organic micro-contaminants (OMCs) enter in freshwaters and interact with other contaminants such as carbon nanoparticles, becoming a problem of unknown consequences for river ecosystems. Carbon nanoparticles (as fullerenes C60) are good adsorbents of organic contaminants and their interaction can potentially
Mara Z Vitolins et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(32), 4092-4098 (2013-10-02)
Hot flashes occur in approximately 80% of androgen-deprived men. Few intervention studies have been conducted to relieve hot flashes in men. Eligible androgen-deprived men were randomly assigned to one of four daily regimens (2 × 2 factorial design) for 12
M Batista et al.
Clinical toxicology (Philadelphia, Pa.), 51(2), 92-95 (2013-01-11)
Venlafaxine is a bicyclic antidepressant that may be associated with severe cardiotoxicity following large overdose. The purpose of this short case series is to present different patterns of venlafaxine-related cardiotoxicity and to discuss the potential mechanisms. Between January 2010 and
View All Related Papers